Added to YB: 2026-07-15
Pitch date: 2026-07-12
CUV.AX [neutral]
Clinuvel Pharmaceuticals Limited
-3.87%
current return
Author Info
Quality Stocks helps you find valuable insights to become a better investor, discover quality companies, and find investment ideas. Sign up for the newsletter.
Company Info
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
Market Cap
AUD 517.9M
Pitch Price
AUD 10.60
Price Target
N/A
Dividend
0.49%
EV/EBITDA
6.48
P/E
15.96
EV/Sales
2.96
Sector
Biotechnology
Category
value
My 12 Picks for 2026, Q1 Performance Review - Clinuvel Pharmaceuticals Limited
CUV.AX (update): Record H1 sales, but near-term profits compressed by deliberate 22% R&D/clinical trial spend to front-load future pipeline. Market mispricing this short-term margin headwind at ~14x PE. Mid-term thesis intact; key inflection year 2028.
Read full article (1 min)